1. Powell, PA, Carlton, J, Rowen, D, et al. Measuring what matters: little evidence supporting the content validity of EQ-5D in people with Duchenne muscular dystrophy and their caregivers. Med Decis Making. 2021.
Google Scholar2. Crossnohere, NL, Fischer, R, Lloyd, A, Prosser, LA, Bridges, JFP. Assessing the appropriateness of the EQ-5D for Duchenne muscular dystrophy: a patient-centered study. Med Decis Making. 2021;41(2):209–21.
Google Scholar | SAGE Journals3. Perfetto, EM, Oehrlein, EM, Boutin, M, Reid, S, Gascho, E. Value to whom? The patient voice in the value discussion. Value Health. 2017;20(2):286–91.
Google Scholar | Crossref4. Mokkink, LB, Terwee, CB, Patrick, DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539–49.
Google Scholar | Crossref | Medline5. Crossnohere, NL, Brundage, M, Calvert, MJ, et al. International guidance on the selection of patient-reported outcome measures in clinical trials: a review. Qual Life Res. 2021;30(1):21–40.
Google Scholar | Crossref | Medline6. US Food and Drug Administration . Patient-reported outcome measures: use in medical product development to support labeling claims. December 2009. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims
Google Scholar7. Khadka, J, Kwon, J, Petrou, S, Lancsar, E, Ratcliffe, J. Mind the (inter-rater) gap: an investigation of self-reported versus proxy-reported assessments in the derivation of childhood utility values for economic evaluation: a systematic review. Soc Sci Med. 2019;240:112543.
Google Scholar | Crossref | Medline8. Prosser, LA, Hammitt, JK, Keren, R. Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children. Pharmacoeconomics. 2007;25(9):713–26.
Google Scholar | Crossref9. Crossnohere, NL, Fischer, R, Crossley, E, Vroom, E, Bridges, JF. The evolution of patient-focused drug development and Duchenne muscular dystrophy. Exp Rev Pharmacoecon Outcomes Res. 2020;20(1):57–68.
Google Scholar | Crossref | Medline10. Tsai, J-H, Crossnohere, NL, Strong, T, Bridges, JF. Measuring meaningful benefit-risk tradeoffs to promote patient-focused drug development in Prader-Willi syndrome: a discrete-choice experiment. MDM Policy Pract. 2021;6(2):23814683211039457.
Google Scholar | Medline11. Lavelle, TA, Crossnohere, NL, Bridges, JF. Quantifying the burden of hyperphagia in Prader-Willi syndrome using quality-adjusted life-years. Clin Ther. 2021;43(7):1164–78.
Google Scholar | Crossref | Medline12. Powell, PA, Carlton, J, Rowen, D, Chandler, F, Guglieri, M, Brazier, JE. Development of a new quality of life measure for Duchenne muscular dystrophy using mixed methods: the DMD-QoL. Neurology. 2021;96(19):e2438–50.
Google Scholar | Crossref | Medline